T. Lissitchkov

发表

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

J. Oldenburg, A. Klukowska, V. Komrska, 2020, Therapeutic advances in hematology.

Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

J. Oldenburg, T. Lissitchkov, C. Hay, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A

C. Négrier, C. Solomon, R. Klamroth, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

A. Akinc, D. Bevan, K. Pasi, 2017, The New England journal of medicine.

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

K. Pasi, T. Lissitchkov, M. Ragni, 2021, Journal of thrombosis and haemostasis : JTH.

Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A

V. Jiménez‐Yuste, T. Lissitchkov, A. Cid, 2019, Thrombosis and Haemostasis.

An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high‐purity Factor IX concentrate, in patients with severe haemophilia B

T. Lissitchkov, M. Matysiak, A. Páez, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

O. Stasyshyn, T. Rogosch, W. Seifert, 2020, Journal of blood medicine.

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

A. Iorio, M. Mancuso, T. Lissitchkov, 2020, Annals of Hematology.

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

A. Iorio, M. Mancuso, T. Lissitchkov, 2019, Annals of Hematology.

Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A

H. Ehrlich, A. Klukowska, V. Komrska, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy

T. Lissitchkov, D. Peytchev, K. Merkle, 2006, Journal of Cancer Research and Clinical Oncology.

Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

J. Oldenburg, C. Kessler, R. Klamroth, 2019, Therapeutic advances in hematology.

Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients

A. Viswabandya, C. Solomon, C. Djambas Khayat, 2019, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)

C. Joch, K. Kuliczkowski, O. Stasyshyn, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

T. Lissitchkov, J. Windyga, B. Abbuehl, 2016 .

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high‐purity factor IX concentrate, in patients with severe haemophilia B

T. Lissitchkov, J. Aznar, N. Cabrera, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Head‐to‐head comparison of the pharmacokinetic profiles of a high‐purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B

T. Lissitchkov, J. Aznar, A. Moret, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic study of a high‐purity factor IX concentrate (Factor IX Grifols®) with a 6‐month follow up in previously treated patients with severe haemophilia B

T. Lissitchkov, J. Aznar, N. Cabrera, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

B. Konkle, T. Lissitchkov, M. Serban, 2007, Journal of thrombosis and haemostasis : JTH.

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study

H. Ehrlich, A. Klukowska, V. Komrska, 2008, Acta Haematologica.

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

C. Kempton, T. Lissitchkov, M. Manco‐Johnson, 2013, Journal of thrombosis and haemostasis : JTH.

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

K. Pasi, R. Klamroth, T. Lissitchkov, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

E. Santagostino, L. Boggio, C. Négrier, 2016, Blood.

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

E. Santagostino, W. Seifert, M. Mancuso, 2020, Journal of thrombosis and haemostasis : JTH.

Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A

J. Oldenburg, T. Lissitchkov, S. Knaub, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A

Y. Katterle, T. Lissitchkov, A. Solms, 2016, Clinical Pharmacokinetics.

Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With rFVIII-FS in Adults With Severe Hemophilia A (SPINART).

C. Kempton, T. Lissitchkov, M. Manco‐Johnson, 2013 .

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA

C. Négrier, K. Pasi, T. Lissitchkov, 2020 .

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study

T. Lissitchkov, A. Willemze, S. Katragadda, 2021, Blood advances.

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

A. Akinc, D. Bevan, K. Pasi, 2015 .

Efficacy, safety and pharmacokinetic results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Willebrand Factor/factor VIII concentrate (Voncento ®) in subjects with hemophilia A (the SWIFT-HA study)

C. Joch, K. Kuliczkowski, A. Dmoszyńska, 2015 .

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

C. Négrier, K. Pasi, T. Lissitchkov, 2017 .

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series

A. Iorio, T. Lambert, M. Makris, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Creagh, A. Akinc, D. Bevan, 2016 .

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2013 .

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

O. Stasyshyn, T. Lissitchkov, J. Windyga, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

S. Pipe, T. Lissitchkov, M. Becka, 2019, Blood.

Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).

C. Joch, K. Kuliczkowski, A. Dmoszyńska, 2016, Thrombosis research.

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

A. Akinc, D. Bevan, K. Pasi, 2016 .

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study

R. Foà, G. Juliusson, M. Montillo, 2008 .

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

T. Lissitchkov, D. Pulanić, I. Bodó, 2023, Annals of Hematology.

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial

G. Juliusson, M. Montillo, T. Lissitchkov, 2012, British journal of haematology.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

F. Peyvandi, T. Lissitchkov, S. Apte, 2018, Journal of thrombosis and haemostasis : JTH.

In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.

C. Botev, T. Lissitchkov, H. Meryman, 2001, Critical reviews in oncology/hematology.

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.

D. Dunlop, C. Fegan, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes

C. Botev, T. Lissitchkov, H. Meryman, 2003, Cancer Gene Therapy.

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial

C. Solomon, C. Djambas Khayat, F. Peyvandi, 2018, Transfusion.

Pharmacodynamics, Pharmacokinetics and Safety of Bay 1093884, an Antibody Directed Against Human TFPI, in Patients with Factor VIII or IX Deficiency (With and Without Inhibitors): A Phase 1 Study

T. Lissitchkov, S. Willmann, Anita Shah, 2018, Blood.

Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors.

B. Konkle, T. Lissitchkov, M. Serban, 2006 .

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

M. Zilberstein, T. Lissitchkov, A. Willemze, 2023, Research and practice in thrombosis and haemostasis.

Efanesoctocog Alfa Half-Life and Clearance Are Independent of von Willebrand Factor in Severe Hemophilia A: A Post Hoc Analysis from Phase 1/2a Studies

J. Dumont, D. Quon, J. Staber, 2021, Blood.

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

E. Santagostino, T. Lissitchkov, A. Lubetsky, 2012 .

The TRUST Trial: Anti-Drug Antibody Formation In a Patient With Hemophilia With Inhibitors After Receiving The Activated Factor VII Product Bay 86-6150

T. Lissitchkov, H. Ng, P. Koh, 2013 .

First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years

S. Pipe, T. Lissitchkov, H. Eichler, 2021, Blood.

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial

G. Juliusson, M. Montillo, T. Lissitchkov, 2012, British journal of haematology.

Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures

C. Kessler, T. Lissitchkov, A. Srivastava, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A

T. Lissitchkov, S. Knaub, J. Bichler, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.